MetrioPharm AG
New class of drugs for early-intervention treatment
MetrioPharm AG is developing a new class of drugs for early-intervention treatment and long-term control of chronic inflammation towards the goal of reversing and preventing diseases of aging. Inflammation is a root cause of the decline in health and chronic degenerative diseases.
Controlling chronic inflammation holds great promise for extending prime health into very old age for the majority of people. Our drug candidates have shown the potential to be significantly safer and more tolerable than existing therapies. MetrioPharm's lead compound MP1032 is currently in Phase II clinical testing. MetrioPharm is headquartered in Zurich and operates a research facility in Berlin.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
22.10.2021
MetrioPharm erhält Kapital für Phase-II-Studien (startupticker.ch)
20.08.2021
Neue CEOs und ein Marketingchef von einem Unicorn (startupticker.ch)
25.11.2020
Development milestones for startups with Corona solutions (startupticker.ch)
19.08.2019
Corporate promis join startup teams (startupticker.ch)
13.12.2018
MetrioPharm closes financing round of CHF20 million (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
MetrioPharm AG
New class of drugs for early-intervention treatment
Website:
www.metriopharm.com/
Headquarter:
Zürich
Foundation Date:
November 2002
Technology:
- Medtech
Sectors:
- Biotech
- Drug discovery